WO2001074402A3 - Camptothecin conjugates - Google Patents

Camptothecin conjugates Download PDF

Info

Publication number
WO2001074402A3
WO2001074402A3 PCT/US2001/006855 US0106855W WO0174402A3 WO 2001074402 A3 WO2001074402 A3 WO 2001074402A3 US 0106855 W US0106855 W US 0106855W WO 0174402 A3 WO0174402 A3 WO 0174402A3
Authority
WO
WIPO (PCT)
Prior art keywords
compound
camptothecin conjugates
disclosed
camptothecin
conjugates
Prior art date
Application number
PCT/US2001/006855
Other languages
French (fr)
Other versions
WO2001074402A2 (en
Inventor
Simeon M Wrenn
Joseph Rubinfeld
Original Assignee
Supergen Inc
Simeon M Wrenn
Joseph Rubinfeld
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc, Simeon M Wrenn, Joseph Rubinfeld filed Critical Supergen Inc
Priority to EP01914665A priority Critical patent/EP1328296A2/en
Priority to AU2001240026A priority patent/AU2001240026A1/en
Publication of WO2001074402A2 publication Critical patent/WO2001074402A2/en
Publication of WO2001074402A3 publication Critical patent/WO2001074402A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Disclosed is a compound that includes a camptothecin conjugated to a lactone ring protecting moiety. Also disclosed are compositions and kits including the compound, and methods of making and usign the compound.
PCT/US2001/006855 2000-03-31 2001-03-02 Camptothecin conjugates WO2001074402A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01914665A EP1328296A2 (en) 2000-03-31 2001-03-02 Camptothecin conjugates
AU2001240026A AU2001240026A1 (en) 2000-03-31 2001-03-02 Camptothecin conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/540,859 US6629995B1 (en) 2000-03-31 2000-03-31 Camptothecin conjugates
US09/540,859 2000-03-31

Publications (2)

Publication Number Publication Date
WO2001074402A2 WO2001074402A2 (en) 2001-10-11
WO2001074402A3 true WO2001074402A3 (en) 2003-04-17

Family

ID=24157226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006855 WO2001074402A2 (en) 2000-03-31 2001-03-02 Camptothecin conjugates

Country Status (4)

Country Link
US (1) US6629995B1 (en)
EP (1) EP1328296A2 (en)
AU (1) AU2001240026A1 (en)
WO (1) WO2001074402A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
ATE477276T1 (en) * 2002-03-01 2010-08-15 Immunomedics Inc INTERNALIZATION OF ANTI CD74 MONOCLONAL ANTIBODIES AND THEIR USES
ITRM20020306A1 (en) 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti ESTERS IN POSITION 20 OF CAMPTOTECINE.
AU2003288467A1 (en) * 2002-12-13 2004-07-09 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
KR20120073370A (en) 2003-09-17 2012-07-04 넥타르 테라퓨틱스 Multi-arm polymer prodrugs
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
US7462627B2 (en) 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
JP5277417B2 (en) 2006-11-30 2013-08-28 ネクター セラピューティクス Method for preparing a polymer composite
RU2009133793A (en) 2007-02-09 2011-03-20 Энзон Фармасьютикалз, Инк. (Us) TREATMENT OF RESISTANT OR UNRELIABLE CANCER FORMS WITH 7-ETHYL-10-HYDROXYCAMPOTECINE CONJUGATES WITH MULTIPLE CHAIN BRANCHES
US8318795B2 (en) * 2007-03-01 2012-11-27 Cedars-Sinai Medical Center Antioxidant polymers containing [1,2]-dithiolane moieties and uses thereof
WO2009086547A1 (en) * 2008-01-03 2009-07-09 Cedars-Sinai Medical Center Antioxidant nanosphere comprising [1,2]-dithiolane moieties
US8603531B2 (en) * 2008-06-02 2013-12-10 Cedars-Sinai Medical Center Nanometer-sized prodrugs of NSAIDs
CA2732508C (en) 2008-08-11 2016-03-15 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
ES2744975T3 (en) 2008-09-23 2020-02-27 Nektar Therapeutics Metronome dosage method with camptothecin prodrugs (eg PEG-Irinotecan)
KR101493125B1 (en) * 2008-11-24 2015-02-12 세다르스-신나이 메디칼 센터 Antioxidant camptothecin derivatives and antioxidant antineoplastic nanospheres thereof
DK3912643T3 (en) 2009-02-13 2022-10-17 Immunomedics Inc IMMUNOCONJUGATES WITH AN INTRACELLULAR-CLEAVABLE BOND
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
CN102336904B (en) * 2011-09-29 2013-03-27 成都一平医药科技发展有限公司 Multivalent polyglycol (PEG) modifier for camptothecin and derivatives thereof and application of multivalent PEG modifier
EA202092410A1 (en) * 2018-04-06 2021-02-09 Сиэтл Дженетикс, Инк. CONJUGATES OF CAMPTOTHETCIN WITH PEPTIDE
WO2021067820A1 (en) * 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
KR20220079606A (en) * 2019-10-04 2022-06-13 씨젠 인크. Camptothecin Peptide Conjugate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017804A1 (en) * 1997-10-03 1999-04-15 Pharmacia & Upjohn S.P.A. Polymeric derivatives of camptothecins
WO1999017805A1 (en) * 1997-10-03 1999-04-15 Pharmacia & Upjohn S.P.A. Bioactive derivatives of camptothecin
WO2001070275A2 (en) * 2000-03-17 2001-09-27 Cell Therapeutics, Inc. Polyglutamic acid-camptothecin conjugates and methods of preparation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US5674192A (en) * 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US5342348A (en) * 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
US5464650A (en) * 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US20020164374A1 (en) * 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
US6485514B1 (en) * 1997-12-12 2002-11-26 Supergen, Inc. Local delivery of therapeutic agents
US6057303A (en) * 1998-10-20 2000-05-02 Bionumerik Pharmaceuticals, Inc. Highly lipophilic Camptothecin derivatives
US6291676B1 (en) * 1999-03-03 2001-09-18 University Of Kentucky Research Foundation Water-soluble derivatives of camptothecin/homocamptothecin
US6207832B1 (en) * 1999-04-09 2001-03-27 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
US6468522B1 (en) * 1999-07-22 2002-10-22 University Of Medicine And Dentistry Of New Jersey Controlled release of thioamide moiety-containing therapeutic agents
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017804A1 (en) * 1997-10-03 1999-04-15 Pharmacia & Upjohn S.P.A. Polymeric derivatives of camptothecins
WO1999017805A1 (en) * 1997-10-03 1999-04-15 Pharmacia & Upjohn S.P.A. Bioactive derivatives of camptothecin
WO2001070275A2 (en) * 2000-03-17 2001-09-27 Cell Therapeutics, Inc. Polyglutamic acid-camptothecin conjugates and methods of preparation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CONOVER C D ET AL: "CAMPTOTHECIN DELIVERY SYSTEMS: ENHANCED EFFICACY AND TUMOR ACCUMULATION OF CAMPTOTHECIN FOLLOWING ITS CONJUGATION TO POLYETHYLENE GLYCOL VIA A GLYCINE LINKER", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 42, no. 5, 1998, pages 407 - 414, XP001023467, ISSN: 0344-5704 *
GREENWALD R B ET AL: "CAMPTOTHECIN-20-PEG ESTER TRANSPORT FORMS: THE EFFECT OF SPACER GROUPS ON ANTITUMOR ACTIVITY", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 6, 1998, pages 551 - 562, XP000985272, ISSN: 0968-0896 *
LERCHEN H-G: "CAMPTOTHECIN ANTITUMOR AGENTS", IDRUGS, CURRENT DRUGS LTD, GB, vol. 2, no. 9, 1999, pages 896 - 906, XP000971262, ISSN: 1369-7056 *
See also references of EP1328296A2 *

Also Published As

Publication number Publication date
US6629995B1 (en) 2003-10-07
AU2001240026A1 (en) 2001-10-15
EP1328296A2 (en) 2003-07-23
WO2001074402A2 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
WO2001074402A3 (en) Camptothecin conjugates
PL341187A1 (en) Novel erythropoietin conjugate, compoaition of erythropoietin conjugates, pharmacological agent, application of erythropoietin conjugates and their compositions as well as method of obtaining novel erythropoietin conjugates
AU2001276048A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
AU2001270413A1 (en) Improved liposomal camptothecins and uses thereof
EP1378505A4 (en) Method of synthesizing camptothecin-relating compounds
CA2475113A1 (en) Isothiazole derivatives useful as anticancer agents
BE2011C028I2 (en) Macrocyclic analogs and methods of their use and preparation
AU2001258359A1 (en) Ir-absorbing compositions
WO2003020700A3 (en) SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF
CA2419314A1 (en) Preparation of risperidone
AU4035595A (en) Crystalline paclitaxel hydrates
AU1743201A (en) Receptor binding conjugates
AU2001288976A1 (en) Compositions and methods of use for extracts of rutaceae plants
WO2001052826A3 (en) Novel podophyllotoxin compositions
WO1998040104A3 (en) Covalent conjugates of topoisomerase i and topoisomerase ii inhibitors
AU2002215904A1 (en) Compounds with a branched linker
AU1342001A (en) Enhancement of production of camptothecins from plants
AU2001273785A1 (en) Range hood
AU2002239739A1 (en) Compositions, methods and kits relating to remodelin
AU7030700A (en) Preparation of highly pure toxin fragments
EA200100564A1 (en) PREPARATION REDUCING PROLACTINE EXTRACT
AU5368699A (en) Derivatives of triptolide, and preparation and uses thereof
AU2001270310A1 (en) Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
AU2844801A (en) Fuel compositions
WO2001066524A3 (en) Intermediates useful for the synthesis of huperzine a

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001914665

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001914665

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP